Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.
NCT00365352 is registered in ClinicalTrials.gov with XenoPort, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.
- Lead sponsor
- XenoPort, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2006
- Completion date
- December 31, 2007
- Enrollment
- 325 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.